The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD)
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD)
Authors
Keywords
Molecular dynamics simulations, Mutagenesis, PD-1, Binding energy, Drug design
Journal
Cell Communication and Signaling
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-06-07
DOI
10.1186/s12964-018-0239-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1
- (2017) Katarzyna Guzik et al. JOURNAL OF MEDICINAL CHEMISTRY
- An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
- (2017) Shuguang Tan et al. Nature Communications
- Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
- (2016) Zhenkun Na et al. CELL RESEARCH
- Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
- (2016) Ju Yeon Lee et al. Nature Communications
- High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
- (2016) Shoichiro Horita et al. Scientific Reports
- Blocking of the PD-1/PD-L1 Interaction by aD-Peptide Antagonist for Cancer Immunotherapy
- (2015) Hao-Nan Chang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
- (2015) Krzysztof M. Zak et al. STRUCTURE
- g_mmpbsa—A GROMACS Tool for High-Throughput MM-PBSA Calculations
- (2014) Rashmi Kumari et al. Journal of Chemical Information and Modeling
- Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity
- (2013) Elena Gianchecchi et al. AUTOIMMUNITY REVIEWS
- GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit
- (2013) Sander Pronk et al. BIOINFORMATICS
- Structure and Interactions of the Human Programmed Cell Death 1 Receptor
- (2013) Xiaoxiao Cheng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
- (2013) Li Shi et al. Journal of Hematology & Oncology
- Free Energy Calculations by the Molecular Mechanics Poisson−Boltzmann Surface Area Method
- (2012) Nadine Homeyer et al. Molecular Informatics
- The role of the PD-1 pathway in autoimmunity and peripheral tolerance
- (2011) Brian T. Fife et al. Annals of the New York Academy of Sciences
- Inverse correlation of programmed death 1 (PD-1) expression in T cells to the spinal radiologic changes in Taiwanese patients with ankylosing spondylitis
- (2011) Ming-Han Chen et al. CLINICAL RHEUMATOLOGY
- PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+T cells
- (2011) Katarzyna Karwacz et al. EMBO Molecular Medicine
- The future of molecular dynamics simulations in drug discovery
- (2011) David W. Borhani et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- Modulating Protein–Protein Interactions with Small Molecules: The Importance of Binding Hotspots
- (2011) Ratna Rajesh Thangudu et al. JOURNAL OF MOLECULAR BIOLOGY
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- T Cell Activation
- (2009) Jennifer E. Smith-Garvin et al. Annual Review of Immunology
- The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
- (2008) D. Y.-w. Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started